Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBay 36-7620
Description: mGlu1 inverse agonist
Chemical Name: (3aS,6aS)-Hexahydro-5-methylene-6a-(2-naphthalenylmethyl)-1H-cyclopenta[c]furan-1-one
Purity: ≥98% (HPLC)
Biological Activity for Bay 36-7620
Bay 36-7620 is a selective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 μM) with inverse agonist activity. Impairs classical conditioning and associated synaptic plasticity in hippocampal neurons. Exhibits neuroprotective and anticonvulsive effects in vivo following systemic administration.
Licensing Information
Sold for research purposes under agreement from Bayer
Technical Data for Bay 36-7620
| M. Wt | 278.35 |
| Formula | C19H18O2 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 232605-26-4 |
| PubChem ID | 9903757 |
| InChI Key | CVIRWLJKDBYYOG-MJGOQNOKSA-N |
| Smiles | C=C1C[C@@]2([H])[C@@](C(OC2)=O)(CC3=CC(C=CC=C4)=C4C=C3)C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Bay 36-7620
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 27.84 | 100 | |
| ethanol | 27.84 | 100 |
Preparing Stock Solutions for Bay 36-7620
The following data is based on the product molecular weight 278.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.59 mL | 17.96 mL | 35.93 mL |
| 5 mM | 0.72 mL | 3.59 mL | 7.19 mL |
| 10 mM | 0.36 mL | 1.8 mL | 3.59 mL |
| 50 mM | 0.07 mL | 0.36 mL | 0.72 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Bay 36-7620
References for Bay 36-7620
References are publications that support the biological activity of the product.
Carroll et al (2001) BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol.Pharmacol. 59 965 PMID: 11306677
De Vry et al (2001) Neuroprotective and behavioural effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620. Eur.J.Pharmacol. 428 203 PMID: 11675037
Gil-Sanz et al (2007) Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice. Cereb.Cortex 18 1653 PMID: 18024992
If you know of a relevant reference for Bay 36-7620, please let us know.
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group I Receptor Inverse Agonists
Keywords: Bay 36-7620, Bay 36-7620 supplier, Bay367620, selective, non-competitive, mGlu1, mGluR1, antagonists, receptors, inverse, agonists, metabotropic, glutamate, Glutamate, (Metabotropic), Group, I, Receptors, 2501, Tocris Bioscience
9 Citations for Bay 36-7620
Citations are publications that use Tocris products. Selected citations for Bay 36-7620 include:
Le et al (2010) The glutamate release inhibitor R.zole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 130 2240 PMID: 20505744
Tronson et al (2010) Metabotropic glutamate receptor 5/Homer interactions underlie stress effects on fear. Autophagy 68 1007 PMID: 21075228
Pallo et al (2016) Mechanisms of tau and Aβ-induced excitotoxicity. Brain Res 1634 119 PMID: 26731336
Sexton et al (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8 16008 PMID: 30375476
Veettil et al (2014) Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation. PLoS Pathog 10 e1004389 PMID: 25299066
Wall et al (2014) Disruption of GRM1-mediated signalling using R.zole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res 27 263 PMID: 24330389
Dolfi et al (2017) R.zole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget 8 44639 PMID: 28591718
Speyer et al (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132 565 PMID: 21681448
Foong (2009) mGluR(1) Receptors Contribute to Non-Purinergic Slow Excitatory Transmission to Submucosal VIP Neurons of Guinea-Pig Ileum. Front Neurosci 3 46 PMID: 20582273
Do you know of a great paper that uses Bay 36-7620 from Tocris? Please let us know.
Reviews for Bay 36-7620
There are currently no reviews for this product. Be the first to review Bay 36-7620 and earn rewards!
Have you used Bay 36-7620?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.